Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial
Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What is the rationale for using pembrolizumab in combination with chemotherapy in the first-line treatment of advanced urothelial cancer? (0:14)
- Could you give us an overview of the aims and design of the KEYNOTE-361 trial? (1:58)
- What were the efficacy and safety findings of this study? (3:40)
- Why do you think the primary endpoint was not met? (5:54)
- How will these findings impact on the role of pembrolizumab in the treatment of advanced urothelial cancer and what future studies involving pembrolizumab in urothelial cancer are planned or are in progress? (8:40)
Speaker Disclosure: Ajjai Alva has been an advisory board member/consultant for Merck Sharp & Dohme Corp, Bristol-Myers Squibb, AstraZeneca, Genentech, Roche, Pfizer, Progenics and Prometheus; has received travel/accommodations/expenses from Merck Sharp Dohmen Corp, Bristol-Myers Squibb and has received research funding through institution from Merck Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb, Astellas, Seattle Genetics, Genentech, Pfizer, Progenics, Prometheus, Eli Lilly, ASCO, Celgene and Harpoon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. The KEYNOTE-361 trial was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Filmed in coverage of the Virtual 2020 ESMO Congress.
PFS = progression-free survival.
Share this Video
Related Videos In Genitourinary Cancer
Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer and therefore the possibility of avoiding surgery; improving prognostic factors and diagnosis in early disease […]
Arnulf Stenzl, EAU23: Latest developments in urological oncology
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Minimalise any uro-oncologic surgery, more precise, complete removal of tumour, improving outcomes (00:37) Developments in robot-assisted surgery […]
Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)
It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Meetings and introducing more virtual, web-based education post-COVID (00:20) Projects, real-world data, future strategies (3:30) Development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!